Developer docs
API playgroundTry for free, no card

Search company profiles

Genesis Therapeutics

Full company profile

uuid028q72z

Namestring
Genesis Therapeutics
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Genesis Therapeutics, operating as Genesis Molecular AI, develops an AI-driven platform for small molecule drug discovery that combines proprietary foundation models with physics-based methods. The company targets challenging biological targets where traditional discovery methods have historically high failure rates, and serves major pharmaceutical companies alongside its own internal drug programs.

The core product stack centers on GEMS (Genesis Exploration and Modeling System), an AI operating system for molecular design that runs end-to-end researcher workflows, and Pearl, a next-generation foundation model purpose-built for molecular-scale AI rather than adapted from general-purpose code or image models. The roadmap also includes advanced capabilities such as Model Distillation for efficient deployment and a Zero-shot Pearl System that, per company reporting, surpassed all cofolding models on the OpenBind benchmark. Each cycle on each drug program is intended to generate new molecular data that feeds back into model improvement, creating an internal data flywheel.

Genesis operates a B2B platform model. Revenue mechanics are not publicly disclosed, but the company markets directly to pharmaceutical enterprises, with Incyte as the publicly named strategic partner following an expanded collaboration announced in June 2026. The company appears to be a privately held, venture-backed entity based on the absence of tickers, exchange listings, or investor-relations material in the available sources; ownership structure, funding history, headcount, and financial details are not disclosed in the input data.

Short descriptiontext

Genesis Therapeutics (dba Genesis Molecular AI) develops AI foundation models combined with physics-based methods for small molecule drug discovery, serving pharmaceutical partners through its GEMS platform and proprietary Pearl foundation model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBurlingame, United States
HQ citystring
Burlingame
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, small molecule therapeutics, molecular foundation models, computational chemistry, pharmaceutical AI platform
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery Platform
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1GEMS
Description

The AI operating system for molecular design - an AI platform powered by industry-leading models for drug discovery research workflows.

genesis.ml
+3 more records
Core offering1 text field

Genesis Therapeutics operates an AI drug discovery platform that combines proprietary foundation models with physics-based methods to design small molecule therapeutics for challenging biological targets. Its core offerings include the GEMS AI operating system for molecular design workflows and the Pearl foundation model, used both for the company's own drug programs and for major pharmaceutical partners such as Incyte.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Genesis Molecular AI is a unified platform for small molecule drug discovery that combines AI foundation models with physics-based methods. The portfolio includes GEMS (Genesis Exploration and Modeling System), the AI operating system for molecular design that powers the entire workflow, and Pearl Foundation Model, a next-generation foundation model for molecular-scale AI. The platform unifies foundation models with physics to enable researchers to run complete design workflows, generating new data that feeds back into improved AI model capabilities. It serves both Genesis's internal drug programs and major pharmaceutical partners.

Product and service3 records
1GEMS (Genesis Exploration and Modeling System)
CategoryAI Platform / Drug Discovery Operating System
Description

The AI operating system for molecular design that powers Genesis's full drug discovery workflow; researchers run their complete design workflow on this platform, powered by the company's most advanced AI models.

2Pearl Foundation Model
CategoryAI Foundation Model
Description

Next-generation foundation model purpose-built for molecular-scale drug discovery; powers molecular design and is the underlying model for the Pearl System on the OpenBind benchmark.

3Genesis Molecular AI Platform
CategoryAI Drug Discovery Platform
Description

Unified platform that combines AI foundation models with physics-based methods for small molecule drug discovery, available to major pharmaceutical partners and used internally for Genesis's own drug programs.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Incyte partnership expansion announced June 10, 2026. Genesis provides AI-powered molecular design capabilities that complement Incyte's drug development expertise. The partnership expansion builds on an existing collaboration to advance small molecule drug discovery programs using Genesis's AI platform.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven small molecule drug discovery company using structure-based and virtual screening approaches with multiple pharma partnerships. Directly comparable platform-and-partnership model focused on small molecules.

TypeOthers
Description

Contract research organization combining automated lab robotics with AI for drug discovery experimentation. Adjacent enabling peer providing experimental data infrastructure that AI-native discovery platforms rely on for the wet-lab validation loop.

3Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind spinoff applying AlphaFold-era AI foundation models to drug discovery and partnering with major pharma. Directly comparable in foundation-model-first approach and pharma partnership GTM.

TypeDirect peer
Description

AI-native drug discovery company combining generative AI, biology, and chemistry to discover and develop small molecule drugs for challenging targets. Closely comparable to Genesis in target focus, platform model, and pharma partnership approach.

TypeDirect peer
Description

Public computational chemistry and molecular simulation platform serving pharma partners and running internal programs. Comparable to Genesis in combining physics-based methods with AI for small molecule discovery and operating a hybrid platform-plus-pipeline model.

TypeDirect peer
Description

Techbio company combining high-throughput biology with AI/ML for drug discovery across multiple therapeutic areas. Comparable in AI-driven discovery platform, internal pipeline plus partnerships, and scaling model throughput.

TypeEmerging player
Description

Generative AI platform for biology and protein engineering, applying foundation models to design novel biologics. Comparable in foundation-model-first philosophy but focused on proteins rather than small molecules.

TypeEmerging player
Description

AI/ML-driven antibody engineering platform with a closed-loop design-build-test-learn workflow. Comparable in wet-lab-integrated AI platform approach but focused on biologics rather than small molecules.

TypeDirect peer
Description

AI + robotics drug discovery company combining physics-based modeling, AI, and automated synthesis for small molecule R&D. Comparable platform approach and pharma partnership commercialization model.

10Iambic Therapeutics
TypeDirect peer
Description

AI-native drug discovery company developing foundation models for chemistry and biology to design small molecule therapeutics. Closely comparable in foundation model approach to molecular design and pharma collaboration strategy.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genesis Therapeutics

AI Drug Discovery Platformgenesistherapeutics.ai

Genesis Therapeutics (dba Genesis Molecular AI) develops AI foundation models combined with physics-based methods for small molecule drug discovery, serving pharmaceutical partners through its GEMS platform and proprietary Pearl foundation model.

What Genesis Therapeutics does

Genesis Therapeutics, operating as Genesis Molecular AI, develops an AI-driven platform for small molecule drug discovery that combines proprietary foundation models with physics-based methods. The company targets challenging biological targets where traditional discovery methods have historically high failure rates, and serves major pharmaceutical companies alongside its own internal drug programs.

The core product stack centers on GEMS (Genesis Exploration and Modeling System), an AI operating system for molecular design that runs end-to-end researcher workflows, and Pearl, a next-generation foundation model purpose-built for molecular-scale AI rather than adapted from general-purpose code or image models. The roadmap also includes advanced capabilities such as Model Distillation for efficient deployment and a Zero-shot Pearl System that, per company reporting, surpassed all cofolding models on the OpenBind benchmark. Each cycle on each drug program is intended to generate new molecular data that feeds back into model improvement, creating an internal data flywheel.

Genesis operates a B2B platform model. Revenue mechanics are not publicly disclosed, but the company markets directly to pharmaceutical enterprises, with Incyte as the publicly named strategic partner following an expanded collaboration announced in June 2026. The company appears to be a privately held, venture-backed entity based on the absence of tickers, exchange listings, or investor-relations material in the available sources; ownership structure, funding history, headcount, and financial details are not disclosed in the input data.

Genesis Therapeutics firmographics

Firmographics
Name
Genesis Therapeutics
Website
https://genesistherapeutics.ai
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Genesis Therapeutics (dba Genesis Molecular AI) develops AI foundation models combined with physics-based methods for small molecule drug discovery, serving pharmaceutical partners through its GEMS platform and proprietary Pearl foundation model.
Ownership category
akta.pro rank

Genesis Therapeutics industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Small molecule therapeutics
  • Molecular foundation models
  • Computational chemistry
  • Pharmaceutical AI platform

Where Genesis Therapeutics is headquartered

Location

Headquarters

HQ city
Burlingame
HQ country
United States
HQ region
North America

Markets served

Genesis Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels2 records

Genesis Therapeutics product offering

Product offering

Core offering

Genesis Therapeutics operates an AI drug discovery platform that combines proprietary foundation models with physics-based methods to design small molecule therapeutics for challenging biological targets. Its core offerings include the GEMS AI operating system for molecular design workflows and the Pearl foundation model, used both for the company's own drug programs and for major pharmaceutical partners such as Incyte.

Product overview

Genesis Molecular AI is a unified platform for small molecule drug discovery that combines AI foundation models with physics-based methods. The portfolio includes GEMS (Genesis Exploration and Modeling System), the AI operating system for molecular design that powers the entire workflow, and Pearl Foundation Model, a next-generation foundation model for molecular-scale AI. The platform unifies foundation models with physics to enable researchers to run complete design workflows, generating new data that feeds back into improved AI model capabilities. It serves both Genesis's internal drug programs and major pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

  • GEMS: The AI operating system for molecular design - an AI platform powered by industry-leading models for drug discovery research workflows.
  • Pearl
  • Genesis Model Distillation
  • Pearl System

Products and services

  • GEMS (Genesis Exploration and Modeling System) The AI operating system for molecular design that powers Genesis's full drug discovery workflow; researchers run their complete design workflow on this platform, powered by the company's most advanced AI models.
  • Pearl Foundation Model Next-generation foundation model purpose-built for molecular-scale drug discovery; powers molecular design and is the underlying model for the Pearl System on the OpenBind benchmark.
  • Genesis Molecular AI Platform Unified platform that combines AI foundation models with physics-based methods for small molecule drug discovery, available to major pharmaceutical partners and used internally for Genesis's own drug programs.

Companies that use Genesis Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Genesis Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Genesis Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • IncytecoreStrategic or Co-development Partner · 10 June 2026Incyte partnership expansion announced June 10, 2026. Genesis provides AI-powered molecular design capabilities that complement Incyte's drug development expertise. The partnership expansion builds on an existing collaboration to advance small molecule drug discovery programs using Genesis's AI platform.

Recent moves4 records

Expansion highlights4 records

Genesis Therapeutics competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI-driven small molecule drug discovery company using structure-based and virtual screening approaches with multiple pharma partnerships. Directly comparable platform-and-partnership model focused on small molecules.
  • Isomorphic Labs: Alphabet/DeepMind spinoff applying AlphaFold-era AI foundation models to drug discovery and partnering with major pharma. Directly comparable in foundation-model-first approach and pharma partnership GTM.
  • Insilico Medicine: AI-native drug discovery company combining generative AI, biology, and chemistry to discover and develop small molecule drugs for challenging targets. Closely comparable to Genesis in target focus, platform model, and pharma partnership approach.
  • Schrödinger, Inc. Public computational chemistry and molecular simulation platform serving pharma partners and running internal programs. Comparable to Genesis in combining physics-based methods with AI for small molecule discovery and operating a hybrid platform-plus-pipeline model.
  • Recursion Pharmaceuticals: Techbio company combining high-throughput biology with AI/ML for drug discovery across multiple therapeutic areas. Comparable in AI-driven discovery platform, internal pipeline plus partnerships, and scaling model throughput.
  • XtalPi: AI + robotics drug discovery company combining physics-based modeling, AI, and automated synthesis for small molecule R&D. Comparable platform approach and pharma partnership commercialization model.
  • Iambic Therapeutics: AI-native drug discovery company developing foundation models for chemistry and biology to design small molecule therapeutics. Closely comparable in foundation model approach to molecular design and pharma collaboration strategy.

Others

  • Arctoris: Contract research organization combining automated lab robotics with AI for drug discovery experimentation. Adjacent enabling peer providing experimental data infrastructure that AI-native discovery platforms rely on for the wet-lab validation loop.

Emerging players

  • Cradle Bio: Generative AI platform for biology and protein engineering, applying foundation models to design novel biologics. Comparable in foundation-model-first philosophy but focused on proteins rather than small molecules.
  • BigHat Biosciences: AI/ML-driven antibody engineering platform with a closed-loop design-build-test-learn workflow. Comparable in wet-lab-integrated AI platform approach but focused on biologics rather than small molecules.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Genesis Therapeutics social profiles

Digital presence

Genesis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genesis Therapeutics leadership team

Management profile

Number of profiles

Genesis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genesis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Therapeutics

What does Genesis Therapeutics do?

Genesis Therapeutics operates an AI drug discovery platform that combines proprietary foundation models with physics-based methods to design small molecule therapeutics for challenging biological targets. Its core offerings include the GEMS AI operating system for molecular design workflows and the Pearl foundation model, used both for the company's own drug programs and for major pharmaceutical partners such as Incyte.

When was Genesis Therapeutics founded?

Genesis Therapeutics was founded in 2019. It employs 101 to 250 people.

Where is Genesis Therapeutics based?

Genesis Therapeutics is headquartered in Burlingame, United States, in the North America region.

Who are Genesis Therapeutics's main competitors?

Direct peers on record are Atomwise, Isomorphic Labs, Insilico Medicine, Schrödinger, Inc., Recursion Pharmaceuticals, XtalPi and Iambic Therapeutics. Arctoris is listed as an others. Emerging players are Cradle Bio and BigHat Biosciences.

Does Genesis Therapeutics have an API?

No public API is recorded for Genesis Therapeutics.

What industry is Genesis Therapeutics in?

Genesis Therapeutics's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldGenesis Molecular AI discloses new PI3Kα mutant inhibitorsGenesis Molecular AI Inc. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) mutant inhibitors, potentially useful for cancer treatment. The company disclosed these inhibitors on July 16, 2026, in a BioWorld Science report.Consainsights5 Best Gen AI Tools For Drug Discovery (2025)The article profiles five generative AI tools—Insilico Medicine, Atomwise, BenevolentAI, Genesis Therapeutics, and BioGPT—that are currently transforming drug discovery through faster molecule design and target prediction. It outlines key features, advantages, and limitations of each platform while highlighting broader industry challenges such as data quality, model interpretability, and regulatory compliance.Mordor IntelligenceAI in Drug Discovery Market Size, Growth & Drivers Research Report 2030Mordor Intelligence reports that the global Artificial Intelligence in Drug Discovery market is valued at USD 2.58 billion in 2025 and is projected to reach USD 8.18 billion by 2030, growing at a CAGR of 25.94%. This expansion is driven by pharmaceutical companies seeking to reduce R&D costs and accelerate discovery timelines through AI partnerships and proprietary data assets. Recent strategic alliances, including significant deals between Pfizer and PostEra, Novartis and Generate: Biomedicines, and Incyte and Genesis Therapeutics, highlight the sector's rapid consolidation and investment.AI InsiderIncyte and Genesis Therapeutics Announce AI-Powered Drug Discovery CollaborationIncyte and Genesis Therapeutics announced a partnership to use Genesis' AI platform GEMS for drug discovery. Incyte gets exclusive rights to clinical and commercial opportunities, with Genesis receiving $30M upfront and up to $295M per target plus royalties. The collaboration targets two initial compounds, with Incyte able to nominate an additional target.BakermckenzieBaker McKenzie Advises Incyte in Its AI-focused Research Collaboration with Genesis TherapeuticsIncyte has entered into a strategic collaboration agreement with Genesis Therapeutics to utilize its AI platform, GEMS, for discovering novel small molecule medicines. The deal includes a USD 30 million upfront payment and potential milestone payments of up to USD 295 million per target, with options to expand to additional targets. Baker McKenzie advised Incyte on this transaction.GenengnewsIncyte, Genesis Therapeutics Partner on AI-Based Small Molecule CollaborationIncyte and Genesis Therapeutics have entered a collaboration to research, discover, and develop small molecule treatments using Genesis's AI platform, with potential value reaching up to $620 million for Genesis. Incyte holds exclusive rights for clinical development and commercialization of the products from at least two initial targets selected by Incyte. This partnership marks the fourth major biopharma agreement for Genesis, following collaborations with Gilead Sciences, Eli Lilly, and Genentech.MorningstarIncyte and Genesis Therapeutics Announce Strategic AI-focused Research CollaborationIncyte and Genesis Therapeutics announced a strategic collaboration to use Genesis' GEMS AI platform for small molecule drug discovery. Incyte gets exclusive rights, with an upfront $30 million payment and potential up to $295 million in milestones per target.Business InsiderIncyte: Genesis Therapeutics to receive $30M upfront in AI collaborationIncyte and Genesis Therapeutics announced a strategic collaboration to develop small molecule medicines, with Genesis receiving a $30 million upfront payment. The partnership targets two initial targets, with Incyte able to nominate an additional one for a fee. Genesis could earn up to $295 million in milestone payments per target if all milestones are achieved.FierceBiotechChutes & Ladders—AI firm Xaira powers up C-suite with pharma vetThis article provides a weekly roundup of significant leadership changes and corporate restructuring events across the biotechnology and pharmaceutical industries. Key highlights include Xaira Therapeutics appointing new C-suite executives, Genesis Therapeutics expanding its management team for its AI platform, and Carisma Therapeutics executing workforce reductions and discontinuing its clinical asset.YahooNVIDIA Invests in Genesis Therapeutics to Advance AI-Powered Drug DevelopmentNVIDIA's NVentures invested in Genesis Therapeutics, a London-based AI biotech, to support its GEMS platform for small-molecule drug discovery. The funding follows a $200 million Series B round and aims to enhance computational strategies for protein structures and molecular data. Genesis plans to bring its first AI-developed drugs into clinical phases.